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The incidence of abnormal placentation, including
placenta accreta, increta and percreta, ranges from 1
in 540 to 1 in 93,000 deliveries [1]. Placenta percreta is
defined as the penetration of trophoblastic tissue into
the myometrium or serosa of the uterus. Severe hem-
orrhage may occur with attempts to manually separate
the placenta from the uterus following delivery. The in-
creased frequency of cesarean delivery over the past two
decades has resulted in a greater incidence of abnormal
placentation as more women enter into subsequent pre-
gnancies with a history of operative deliveries [2]. The
treatment of abnormal placentation has evolved with
time. We report a case of placenta previa totalis and
extensive percreta that was successfully managed with
preservation of the uterus.
A 32-year-old woman, gravida 2, para 1, was referred
to our hospital at 7 weeks of gestation for evaluation of
an asymptomatic pregnancy within a cesarean scar, as
demonstrated by ultrasound. She had a history of ce-
sarean section with an incision in the lower uterine seg-
ment. Termination of the pregnancy was recommended.
However, the patient decided to continue the pregnancy
because of religious beliefs. The antenatal examinations
were unremarkable with the exception of intermittent
painless vaginal spotting. An ultrasound examination
at 27 weeks of gestation showed the absence of a nor-
mal subplacental sonolucent layer and deep invasion
of the anterior lower uterine segment by the placenta.
Magnetic resonance imaging (MRI) at 32 weeks of ges-
tation demonstrated that the placenta occupied the
entire lower uterine segment with some obliteration of
the uteroplacental interface and small serosal interrup-
tions of the left posterior wall of the bladder without
mucosal invasion (Figure 1). The findings were consistent
with a diagnosis of placenta percreta.
A classical cesarean section was performed at 34+
weeks of gestation, after ultrasound examination indi-
cated an adequate fetal body weight. Angioemboli-
zation catheters were placed bilaterally through the
femoral arteries on the morning of surgery. At laparot-
omy, the previous cesarean scar was nearly completely
dehiscent and involved the lower one-third of the
uterus. The placenta was visualized beneath a paper-thin
membrane-like peritoneum covering the area of dehis-
cence, and engorged blood vessels crossing through
the membrane were noted (Figure 2). The fetus was
delivered via breech extraction, and had Apgar scores
of 5 and 9 at 1 and 5 minutes, respectively. The placenta
was not removed and was left in place. Immediately
after the infant was delivered, bilateral transarterial
embolization of the internal iliac arteries using Gelfoam
was performed by radiologists present in the delivery
room. The embolization technique was done as previ-
ously described [3]. The amount of intraoperative blood
loss was approximately 2,000 mL. The postoperative
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Figure 1. Obliteration of the uteroplacental interface and small
serosal interruption in the left posterior wall of the bladder
without mucosal invasion (arrows). The arrowhead indicates
the fetal part. P = placenta.
course was uneventful and the patient was discharged
on the 13th postoperative day.
During follow-up in the outpatient department,
serial abdominal ultrasonography and serum β-human
chorionic gonadotropin (β-hCG) levels were used to
monitor the involution of the uterus and the placenta.
Methotrexate (50 mg) was administered intramuscularly
on the 30th, 32nd and 34th postoperative days because
of an unsatisfactory decline in the β-hCG level. The
serum β-hCG level subsequently decreased to normal
68 days after methotrexate therapy was initiated. A ne-
crotic mass measuring 5 cm × 2 cm × 2 cm was expelled
from the vagina on the 108th postoperative day. Ultra-
sonographic examination on the 164th postoperative
day showed that the placenta had completely regressed.
Menstruation resumed 2 months after normalization
of the uterus, and hysteroscopy revealed sclerotic
changes and local fibrosis of the lower segment of the
uterus.
Placenta percreta is the most serious of placental
implantation anomalies beyond the uterine serosa.
Placenta percreta can only be diagnosed at the time of
delivery, or may be suggested antenatally by ultrasono-
graphic or MRI findings in patients whose clinical his-
tory, such as a previous abdominal delivery, previous
uterine surgery, a suction dilatation and curettage, or
placenta previa, raises a suspicion.
Based on a literature search using MEDLINE, we
identified 11 cases diagnosed with placenta percreta
that were treated conservatively with successful uterine
preservation from 1995 to the present. The Table shows
the pertinent details of each case. Legro et al [4] reported
one case with placenta percreta that was left in situ
after a vaginal delivery. Methotrexate was administered
weekly at a dose of 1mg/kg for 10 weeks. A hysteroscopic
examination showed a normal uterine cavity 8 months
later. In addition, this patient had an uneventful preg-
nancy, labor and vaginal delivery 2 years later. Clement
et al [11] reported two cases with placenta percreta 
in which the placenta was left in situ. One patient was
treated with embolization of the uterine arteries and
the other received no intervention. Both placentas
were spontaneously resorbed between 5 and 6 months
later, and the patients resumed normal menstrual cycles
thereafter. Descargues et al [8] described a successful
experience involving the delayed manual removal of the
placenta 12 days after delivery. Verma and Maggiorotto
[13] reported a case of a second-trimester cervical
pregnancy and placenta percreta treated with a com-
bination of multiple systemic methotrexate injections,
removal of the fetal bones, a cervical cerclage, and
placement of a Foley catheter for control of hemor-
rhage. The patient subsequently had a normal intrauter-
ine pregnancy and delivered a full-term healthy infant
by cesarean section. In general, the prognosis of pla-
centa percreta is good if the placenta is left in situ and
adjuvant therapy, including methotrexate, transarter-
ial embolization of the uterine arteries or both, is given
[4,6,8–12]. The optional use of adjuvant therapy accel-
erates the involution of the placenta. Placentas that
are left in situ continue to involute slowly from weeks to
months and ultimately regress completely.
Placenta previa totalis and percreta can be diagnosed
during the second trimester by Doppler ultrasound or
MRI, although MRI appears to provide a more accurate
diagnosis [14]. The use of MRI has the advantages of
superior image resolution, and precise determination of
the extent of placental invasion into the myometrium
and surrounding organs, such as the bladder.
The involution of the placenta can be assessed by
serial ultrasonography and serum β-hCG titers. The
outcome of leaving the placenta in place varies widely,
and includes complete remission, an intrauterine infec-
tion requiring prolonged administration of antibiotics,
delayed vaginal bleeding and hysterectomy.
In our case, the patient’s desire to continue the
pregnancy provided a unique opportunity to observe the
dynamics of placenta previa totalis and extensive per-
creta. Intraoperative transarterial embolization of the
internal iliac arteries with Gelfoam was used to control
blood loss, reduce blood perfusion into the uterus and
accelerate shedding of the placenta. Methotrexate,
with its anti-trophoblastic effects, enhances the involu-
tion of the placenta, but its use depends on the rate of
decline of the serum β-hCG level.
A successful outcome can be achieved in properly se-
lected candidates by non-surgical treatment of placenta
previa totalis and extensive percreta, with the placenta
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Figure 2. Complete dehiscence of the previous cesarean scar
with a paper-thin membrane-like peritoneum covering. The
prominent engorged vessels (arrows) of the placenta beneath
the peritoneum can be seen.
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Complete Placenta Previa with Percreta 
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left in situ, through the use of intraoperative emboliza-
tion and subsequent methotrexate administration. If
adequate hospital facilities are available, conservative
treatment reduces maternal morbidity and preserves
fertility [9].
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